What is Immunotherapy?

Immunotherapy is a conventional treatment modality that uses pharmaceutical drugs or personalized therapeutic agents to benefit a number of disorders, including auto-immune disorders and cancer. Many of these treatments are considered to be experimental.

This web page is currently under construction - it is in the literature review stage.

Immune Checkpoint Inhibitors

      [Duffy2019]   Michael J Duffy, John Crown. Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients. Clin Chem. 2019 Oct;65(10):1228-1238. Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients PMID: 31315901 DOI:  10.1373/clinchem.2019.303644

Tumor Mutation Burden (TMB)

      [Dong2021]   Aoran Dong, Yiming Zhao, Zhihua Li, Hai Hu. PD-L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non-small cell lung cancer?. J Gene Med. 2021 Feb;23(2):e3294. PMID: 33171529 DOI:  10.1002/jgm.3294 PAYWALL

PMID 32395490

      [Li2020]   Yuan Li, Zuhua Chen, Long Wu, Weiping Tao. Novel tumor mutation score versus tumor mutation burden in predicting survival after immunotherapy in pan-cancer patients from the MSK-IMPACT cohort. Ann Transl Med. 2020 Apr;8(7):446. PMID: 32395490 DOI:  10.21037/atm.2020.03.163 PCMID: PMC7210182

Metastasis

      [Huang2021]   Xin Huang, Xiaoliang Shi, Donghua Huang, Binghao Li, et al. Mutational characteristics of bone metastasis of lung cancer. Ann Palliat Med. 2021 Aug;10(8):8818-8826. PMID: 34488370 DOI:  10.21037/apm-21-1595

Immune Co-inhibitory Receptors

      [Shi2021]   Xiao Shi, Cui-Wei Li, Li-Cheng Tan, Shi-Shuai Wen, et al. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study. J Clin Endocrinol Metab. 2021 Jan 1;106(1):120-132. PMID: 33000173 DOI:  10.1210/clinem/dgaa701 FULL TEXT

Markers

PMID 32278982

      [Fumet2020]   Jean-David Fumet, Caroline Truntzer, Mark Yarchoan, Francois Ghiringhelli. Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts. Eur J Cancer. 2020 May:131:40-50. PMID: 32278982 DOI:  10.1016/j.ejca.2020.02.038 PCMID: PMC9473693

Later

Ovarian Cancer

      [Siminiak2022]   Natalia Siminiak, Rafał Czepczyński, Mikołaj Piotr Zaborowski, Dariusz Iżycki. Immunotherapy in Ovarian Cancer. Arch Immunol Ther Exp (Warsz). 2022 Aug 9;70(1):19. PMID: 35941287 DOI:  10.1007/s00005-022-00655-8 PCMID: PMC9360103

      [Palaia2020]   Innocenza Palaia, Federica Tomao, Carolina Maria Sassu, Lucia Musacchio, Pierluigi Benedetti Panici. Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches. Onco Targets Ther. 2020 Jun 26:13:6109-6129. PMID: 32617007 DOI:  10.2147/OTT.S205950 PCMID: PMC7326187

      [Dotzer2019]   Katharina Dötzer, Friederike Schlüter, Markus Bo Schoenberg, Alexandr V Bazhin, et al. Immune Heterogeneity Between Primary Tumors and Corresponding Metastatic Lesions and Response to Platinum Therapy in Primary Ovarian Cancer. Cancers (Basel). 2019 Aug 26;11(9):1250. PMID: 31455033 DOI:  10.3390/cancers11091250 PCMID: PMC6769550

PMID 36003381

      [Wang2022]   Haoyu Wang, Jingchun Liu, Jiang Yang, Zhi Wang, et al. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer. Front Immunol. 2022 Aug 8:13:943389. PMID: 36003381 DOI:  10.3389/fimmu.2022.943389 PCMID: PMC9393426

PMID 35087563

      [Cui2022]   Mengjing Cui, Qianqian Xia, Xing Zhang, Wenjing Yan, et al. Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Signature for Ovarian Cancers. Front Genet. 2022 Jan 11:12:688207. PMID: 35087563 DOI:  DOI: 10.3389/fgene.2021.688207 PCMID: PMC8787320

PMID 33165430

      [Mi2020]   Jing-Lin Mi, Meng Xu, Chang Liu, Ren-Sheng Wang. Interactions between tumor mutation burden and immune infiltration in ovarian cancer. Int J Clin Exp Pathol. 2020 Oct 1;13(10):2513-2523. PMID: 33165430 PCMID: PMC7642696

PMC7646107

      [Liu2020]   Jinhui Liu, Wei Xu, Siyue Li, Rui Su, Wenjun Cheng. Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database. Int J Med Sci. 2020 Oct 23;17(18):3200-3213. PMID: 33173439 DOI:  10.7150/ijms.50491 PCMID: PMC7646107

PMID 34764678

      [Lu2021]   Nan Lu, Jinhui Liu, Mengting Xu, Jianqiang Liang, et al. CSMD3 is Associated with Tumor Mutation Burden and Immune Infiltration in Ovarian Cancer Patients. Int J Gen Med. 2021 Nov 4:14:7647-7657. PMID: 34764678 DOI:  10.2147/IJGM.S335592 PCMID: PMC8575319

PMID 32774167

      [Bi2020]   Fangfang Bi, Ying Chen, Qing Yang. Significance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of ovarian cancer. Cancer Cell Int. 2020 Aug 5:20:373. PMID: 32774167 DOI:  10.1186/s12935-020-01472-9 PCMID: PMC7405355

PMC9379118

      [Awada2022]   Ahmad Awada, Sarfraz Ahmad, Nathalie D McKenzie, Robert W Holloway. Immunotherapy in the Treatment of Platinum-Resistant Ovarian Cancer: Current Perspectives. Onco Targets Ther. 2022 Aug 10:15:853-866. PMID: 35982728 DOI:  10.2147/OTT.S335936 PCMID: PMC9379118

PMID PMC9379118

      [Pizarro2023]   David Pizarro, Ignacio Romero, Belén Pérez-Mies, Andrés Redondo, et al. The Prognostic Significance of Tumor-Infiltrating Lymphocytes, PD-L1, BRCA Mutation Status and Tumor Mutational Burden in Early-Stage High-Grade Serous Ovarian Carcinoma - A Study by the Spanish Group for Ovarian Cancer Research (GEICO). Int J Mol Sci. 2023 Jul 6;24(13):11183. PMID: 37446361 DOI:  10.3390/ijms241311183 PCMID: PMC10342764

PMID 33189611

      [Fan2020]   Suzhen Fan, Xiang Gao, Qiaohong Qin, Hongyu Li, et al. Association between tumor mutation burden and immune infiltration in ovarian cancer. Int Immunopharmacol. 2020 Dec;89(Pt A):107126. PMID: 33189611 DOI:  10.1016/j.intimp.2020.107126

PMID 38232985

      [Deng2024]   Mengqi Deng, Fan Tang, Xiangyu Chang, Penglin Liu, et al. Immunotherapy for Ovarian Cancer: Disappointing or Promising?. Mol Pharm. 2024 Feb 5;21(2):454-466. PMID: DOI: PMID: 38232985 DOI:  10.1021/acs.molpharmaceut.3c00986 PAYWALL

PMID 33490226

      [Demircan2020]   Nazım Can Demircan, Stergios Boussios, Tolga Tasci, Mehmet Akif Öztürk. Current and future immunotherapy approaches in ovarian cancer. Ann Transl Med. 2020 Dec;8(24):1714. PMID: 33490226 DOI:  10.21037/atm-20-4499 PCMID: PMC7812210

PMC3579897

      [Mantia-Smaldone2012]   Gina M Mantia-Smaldone, Bradley Corr, Christina S Chu. Immunotherapy in ovarian cancer. Hum Vaccin Immunother. 2012 Sep;8(9):1179-91. PMID: 22906947 DOI:  10.4161/hv.20738 PCMID: PMC3579897

PMC6788969

      [Liu2019]   Ying L. Liu, Qin Zhou, Alexia Iasonos, Vivian N. Emengo, et al. Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer. Gynecol Oncol. 2019 Oct; 155(1): 51–57. PMID: 31421916 DOI:  10.1016/j.ygyno.2019.08.006 PCMID: PMC6788969

PMC7572849

      [Yang2020]   Chang Yang, Bai-Rong Xia, Zhao-Cong Zhang, Yong-Jian Zhang, et al. Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant. Front Immunol. 2020 Oct 6:11:577869. PMID: 33123161 DOI:  10.3389/fimmu.2020.577869 PCMID: PMC7572849

PMID 25524384

      [Schwab2014]   Carlton L Schwab, Diana P English, Dana M Roque, Monica Pasternak, Alessandro D Santin. Past, present and future targets for immunotherapy in ovarian cancer. Immunotherapy. 2014;6(12):1279-93. PMID: 25524384 DOI:  10.2217/imt.14.90 PCMID: PMC4312614

PMC2831814

      [Liu2010]   Bei Liu, John Nash, Carolyn Runowicz, Helen Swede, et al. Ovarian cancer immunotherapy: opportunities, progresses and challenges. J Hematol Oncol. 2010 Feb 10:3:7. PMID: 20146807 DOI:  10.1186/1756-8722-3-7 PCMID: PMC2831814

PMC4869278

      [Mittica2016]   Gloria Mittica, Sonia Capellero, Sofia Genta, Celeste Cagnazzo, et al. Adoptive immunotherapy against ovarian cancer. J Ovarian Res. 2016 May 17;9(1):30. PMID: 27188274 DOI:  10.1186/s13048-016-0236-9 PCMID: PMC4869278

PMID 30390758

      [Chodon2018]   Thinle Chodon, Amit A Lugade, Sebastiano Battaglia, Kunle Odunsi. Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer. Hematol Oncol Clin North Am. 2018 Dec;32(6):1025-1039. PMID: 30390758 DOI:  10.1016/j.hoc.2018.07.011 PCMID: PMC7879480

PMID 28169004

      [Krishnan2017]   Venkatesh Krishnan, Jonathan S Berek, Oliver Dorigo. Immunotherapy in ovarian cancer. Curr Probl Cancer. 2017 Jan-Feb;41(1):48-63. PMID: 28169004 DOI:  10.1016/j.currproblcancer.2016.11.003 PAYWALL

PMID 25806106

      [Coukos2016]   G Coukos, J Tanyi, L E Kandalaft. Opportunities in immunotherapy of ovarian cancer. Ann Oncol. 2016 Apr;27 Suppl 1(Suppl 1):i11-i15. PMID: 27141063 DOI:  10.1093/annonc/mdw084 PCMID: PMC4852275

PMC6775498

      [Yang2019]   Siyu Yang, Xiaojiao Yin, Ying Yue, Siqing Wang. Application Of Adoptive Immunotherapy In Ovarian Cancer. Onco Targets Ther. 2019 Sep 27:12:7975-7991. PMID: 31632055 DOI:  10.2147/OTT.S221773 PCMID: PMC6775498

PMC6806629

      [Corradetti2019]   Bruna Corradetti, Simone Pisano, Robert Steven Conlan, Mauro Ferrari. Nanotechnology and Immunotherapy in Ovarian Cancer: Tracing New Landscapes. J Pharmacol Exp Ther. 2019 Sep;370(3):636-646. PMID: 30737357 DOI:  10.1124/jpet.118.254979 PCMID: PMC6806629

PMC3034919

      [Gavalas2011]   Nikos G Gavalas, Alexandra Karadimou, Meletios A Dimopoulos, Aristotelis Bamias. Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization. Clin Dev Immunol. 2010:2010:791603. PMID: 21318181 DOI:  10.1155/2010/791603 PCMID: PMC3034919

PMC7764119

      [Hartnett2020]   Erin G Hartnett, Julia Knight, Mackenzy Radolec, Ronald J Buckanovich, et al. Immunotherapy Advances for Epithelial Ovarian Cancer. Cancers (Basel). 2020 Dec 11;12(12):3733. PMID: 33322601 DOI:  10.3390/cancers12123733 PCMID: PMC7764119

PMC10161148

      [Daniyal2023]   Muhammad Daniyal, Anamm S Polani, Marcy Canary. Ovarian Carcinosarcoma and Response to Immunotherapy. Cureus. 2023 Apr 5;15(4):e37149. PMID: 37153309 DOI:  10.7759/cureus.37149 PCMID: PMC10161148

PMC3566823

      [Hall2013]   M Hall, C Gourley, I McNeish, J Ledermann, et al. Targeted anti-vascular therapies for ovarian cancer: current evidence. Br J Cancer. 2013 Feb 5;108(2):250-8. PMID: 23385789 DOI:  10.1038/bjc.2012.541 PCMID: PMC3566823

PMC3556875

      [Garcia2013]   Agustin Garcia, Harpreet Singh. Bevacizumab and ovarian cancer. Ther Adv Med Oncol. 2013 Mar;5(2):133-41. PMID: 23450196 DOI:  10.1177/1758834012467661 PCMID: PMC3556875

PMC7714556

      [Claussen2020]   Carlota Claussen, Achim Rody, Lars Hanker. Treatment of Recurrent Epithelial Ovarian Cancer. Geburtshilfe Frauenheilkd. 2020 Dec;80(12):1195-1204. PMID: 33293727 DOI:  10.1055/a-1128-0280 PCMID: PMC7714556

PMC2375319

      [Zhang2002]   M Zhang, Z Y Yang, C W Binns, A H Lee. Diet and ovarian cancer risk: a case-control study in China. Br J Cancer. 2002 Mar 4;86(5):712-7. PMID: PMC2375319 PCMID: 10.1038/sj.bjc.6600085

PMID 26787282

      [Narod2016]   Steven Narod. Can advanced-stage ovarian cancer be cured?. Nat Rev Clin Oncol. 2016 Apr;13(4):255-61. PMID: 26787282 DOI:  DOI: 10.1038/nrclinonc.2015.224 PAYWALL

References